Trial reportArchives of internal medicine2008
Reduction in blood pressure with statins: results from the UCSD Statin Study, a randomized trial.
Trial report in Archives of internal medicine, 2008. The graph read 3 numbers from its abstract, feeding 1 cell of the map: it supports the treatment in 1. It reports registered trial NCT00330980. Cited by 50 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
RESULTS: Statins modestly but significantly reduced BP relative to placebo,by 2.2 mm Hg for SBP (P=.02) and 2.4 mm Hg for DBP (P<.001) in ITT analysis.
RESULTS: Statins modestly but significantly reduced BP relative to placebo,by 2.2 mm Hg for SBP (P=.02) and 2.4 mm Hg for DBP (P<.001) in ITT analysis.
Read, but not usablea number the graph found but could not read as for or against
Blood pressure reductions ranged from 2.4 to 2.8 mm Hg for both SBP and DBP with both simvastatin and pravastatin, in those subjects with full follow-up, and without potential for influence by BP medications (ie, neither receiving nor meriting BP medications).
clause the extractor read what became the number
Where it lands on the map
Rows are treatments, columns are outcomes. The coloured squares are the cells this paper feeds, coloured by the vote it casts there. Click one to jump to what this paper adds to it.
What it adds to each cell
For every cell the paper feeds: the belief in the claim with and without this paper, and this paper's estimate drawn against every other readable study in the cell. The ringed dot is this paper.
Statins×blood pressure
SupportsOpen on the map →What to test next →8 readable studies in this cell: 3 favour the treatment, 4 find no difference, 1 favour the comparator.
This paper's own estimate is on a different scale from the rest of the cell, so it is not drawn here.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Statins and Noncardiovascular Endpoints
Open the trial in the graphWho cites it
50 citing papers in PubMed, 2 syntheses or guidelines pooled it, 145 citations in OpenAlex.
- Statin's role on blood pressure levels: Meta-analysis based on randomized controlled trials.Journal of clinical hypertension (Greenwich, Conn.) · 2023Pooled it
- Antihypertensive effects of statins: a meta-analysis of prospective controlled studies.Journal of clinical hypertension (Greenwich, Conn.) · 2013 · on this mapPooled it
- Dual modulation of lipid and glucose metabolism by a nutraceutical combination in patients at cardiometabolic risk: results from a multicenter randomized controlled trial.Cardiovascular diabetology · 2025 · on this mapTrial
- Randomized, multicenter, parallel, open, phase 4 study to compare the efficacy and safety of rosuvastatin/amlodipine polypill versus atorvastatin/amlodipine polypill in hypertension patient with dyslipidemia.Journal of clinical hypertension (Greenwich, Conn.) · 2023Trial
- Central blood pressure lowering effect of telmisartan-rosuvastatin single-pill combination in hypertensive patients combined with dyslipidemia: A pilot study.Journal of clinical hypertension (Greenwich, Conn.) · 2021Trial
- Statin Effects on Aggression: Results from the UCSD Statin Study, a Randomized Control Trial.PloS one · 2015Trial
- Blood pressure-lowering effect of simvastatin: a placebo-controlled randomized clinical trial with 24-h ambulatory blood pressure monitoring.Journal of human hypertension · 2014 · on this mapTrial
- Effects of statins on energy and fatigue with exertion: results from a randomized controlled trial.Archives of internal medicine · 2012Trial
- Statin therapy lowers muscle sympathetic nerve activity and oxidative stress in patients with heart failure.American journal of physiology. Heart and circulatory physiology · 2012Trial
- Simultaneous treatment to attain blood pressure and lipid goals and reduced CV risk burden using amlodipine/atorvastatin single-pill therapy in treated hypertensive participants in a randomized controlled trial.Vascular health and risk management · 2010 · on this mapTrial
- Statins, antihypertensive treatment, and blood pressure control in clinic and over 24 hours: evidence from PHYLLIS randomised double blind trial.BMJ (Clinical research ed.) · 2010 · on this mapTrial
- Atorvastatin in Factorial with Omega-3 EE90 Risk Reduction in Diabetes (AFORRD): a randomised controlled trial.Diabetologia · 2009Trial
- Cytokines, C-Reactive Protein, and Risk of Incident Hypertension in the REGARDS Study.Hypertension (Dallas, Tex. : 1979) · 2024Article
- Review
- Clarification of hypertension mechanisms provided by the research of central circulatory regulation.Hypertension research : official journal of the Japanese Society of Hypertension · 2023Review
- Pharmacometabolomics for the Study of Lipid-Lowering Therapies: Opportunities and Challenges.International journal of molecular sciences · 2023Review
- The association of lipid-lowering therapy and blood pressure control among outpatients with hypertension at the Felege Hiwot Comprehensive Specialized Hospital, Northwest Ethiopia.Frontiers in cardiovascular medicine · 2023Article
- Mechanism Underlying Naringenin Hypocholesterolemic Effects: Involvement of Estrogen Receptor α Subtype.International journal of molecular sciences · 2022Article
- Biochemistry and Nanomechanical Properties of Human Colon Cells upon Simvastatin, Lovastatin, and Mevastatin Supplementations: Raman Imaging and AFM Studies.The journal of physical chemistry. B · 2022Article
- Hypertension and Dyslipidemia Combined Therapeutic Approaches.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2022Review
Corrections and comments
- Commented on by
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
The marked sentences are the ones the graph read a number from.
backgroundSome studies have suggested reductions in blood pressure (BP)with statin treatment, particularly in persons with hypertension. Randomized trial evidence is limited.
methodsWe performed a randomized, double-blind, placebo-controlled trial with equal allocation to simvastatin, 20 mg; pravastatin sodium,40 mg; or placebo for 6 months. Nine hundred seventy-three men and women without known cardiovascular disease or diabetes mellitus, with low-density lipoprotein cholesterol screening levels of 115 to 190 mg/dL, had assessment of systolic and diastolic BP (SBP and DBP, respectively). Blood pressure values were compared for placebo vs statins by intention-to-treat (ITT) analysis. Additional analyses were performed that (1) were confined to subjects with neither high baseline BP (SBP>140 mm Hg or DBP>90 mm Hg) nor receiving BP medications, to exclude groups in whom BP medications or medication changes may have influenced results, and (2) separately evaluated simvastatin and pravastatin (vs placebo). The time course of BP changes after statin initiation and the effect of stopping statins on BP were examined.
resultsStatins modestly but significantly reduced BP relative to placebo,by 2.2 mm Hg for SBP (P=.02) and 2.4 mm Hg for DBP (P<.001) in ITT analysis. Blood pressure reductions ranged from 2.4 to 2.8 mm Hg for both SBP and DBP with both simvastatin and pravastatin, in those subjects with full follow-up, and without potential for influence by BP medications (ie, neither receiving nor meriting BP medications).
conclusionsReductions in SBP and DBP occurred with hydrophilic and lipophilic statins and extended to normotensive subjects. These modest effects may contribute to the reduced risk of stroke and cardiovascular events reported on statins. Trial Registration clinicaltrials.gov Identifier: NCT00330980.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.